Drug intelligence / Profile preview

KV27d

Development stage: Preclinical
Lead developer: Kensana Health
Administration: Topical

Overview

**KV27d** is a preclinical topical phytopharmaceutical cannabinoid wound-therapy candidate developed by Kensana Health for diabetic foot ulcer. It is described as a cannabinoid-based preparation intended to support wound healing through modulation of the endocannabinoid system; however, its constituent cannabinoids, precise molecular targets, receptor pharmacology, formulation, and detailed mechanism have not been publicly disclosed.

Other names: KV 27dKV27dKV-27d

Beyond the preview

Go deeper on KV27d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV27d.

Explore the full profile